Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124122 | 0.89 | HTR2A (0.34) | HTR2AHTR2CHTR2B | |
| SCHEMBL8737441 | 0.84 | MAOA (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL19297008 | 0.81 | HTR2C (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL8737437 | 0.80 | MAOA (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL22016767 | 0.79 | HTR2A (0.31) | HTR2AHTR2CHTR2B | |
| SCHEMBL8053197 | 0.77 | MAOA (0.43) | HTR2AHTR2CHTR2B | |
| SCHEMBL26700017 | 0.76 | PARP1 (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL25146229 | 0.76 | — | — | |
| SCHEMBL17658864 | 0.76 | MAPT (0.35) | — | |
| SCHEMBL22016768 | 0.75 | HTR2A (0.31) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662214-B2 | Compound of 4′-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof | Sichuan Keiun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-20180079770-A1 | NOVEL COMPOUND OF 4'-THIONUCLEOSIDE, AS WELL AS PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662214-B2 | Compound of 4′-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof | TYMP, WEE1, NTPCR | HTR2A 4854/4885HTR2C 4798/4885HTR2B 4809/4885 |
| US-20180079770-A1 | NOVEL COMPOUND OF 4'-THIONUCLEOSIDE, AS WELL AS PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | WEE1, WEE2, THEM6 | HTR2A 4872/4885HTR2C 4805/4885HTR2B 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.